3 reports

  • ETBX-011 - Drug Profile
  • ETBX-011, patients were taken off all other anti-cancer treatment for at least 30 days.

Investigators also will determine if the vaccine/ immunotherapy combination works better than immunotherapy plus chemotherapy and surgery.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Vaccine
  • Etubics Corporation
  • ETBX-011 - Drug Profile
  • ETBX-011, patients were taken off all other anti-cancer treatment for at least 30 days.

Investigators also will determine if the vaccine/ immunotherapy combination works better than if just the immunotherapy drug was given with chemotherapy and surgery.

  • Immunotherapy
  • Lung Cancer
  • Monoclonal Antibody
  • Therapy
  • Etubics Corporation
  • ETBX-011 - Drug Profile
  • ETBX-011, patients were taken off all other anti-cancer treatment for at least 30 days.

Initiation of Atalante ##, the Company' s Global, Pivotal Phase ## Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer OSE Pharma SA, an immuno-oncology company developing a T-specific immunotherapy for late-stage cancer patients, announced initiation in the Uni

  • Immunotherapy
  • Lung Cancer
  • Monoclonal Antibody
  • Therapy
  • Etubics Corporation